Literature DB >> 32374613

Molecular Dynamics Simulations Provide Insight into the Loading Efficiency of Proresolving Lipid Mediators Resolvin D1 and D2 in Cell Membrane-Derived Nanovesicles.

Jeevan B Gc1, Christopher T Szlenk1, Jin Gao1, Xinyue Dong1, Zhenjia Wang1, Senthil Natesan1.   

Abstract

Resolvins D1 and D2 (RvDs) are structural isomers and metabolites of docosahexaenoic acid, an omega-3 fatty acid, enzymatically produced in our body in response to acute inflammation or microbial invasion. Resolvins have been shown to play an essential role in the resolution of inflammation, tissue repair, and return to homeostasis and thus are actively pursued as potential therapeutics in treating inflammatory disorders and infectious diseases. However, effective in vivo delivery of RvDs continues to be a challenging task. Recent studies demonstrated that RvD1 or RvD2 loaded in cell membrane-derived nanovesicles significantly increased therapeutic efficacy in treating murine peritonitis and ischemic stroke, respectively. The mechanistic details of how the subtle structural difference between RvD1 and RvD2 alters their molecular interactions with the membrane lipids of the nanovesicles and thus affects the loading efficiency remain unknown. Here, we report the encapsulation profiles of the neutral and ionized species of both RvD1 and RvD2 determined with the cell membrane-derived nanovesicles at pH values 5.4 and 7.4, respectively. Also, we performed microsecond time-scale all-atom molecular dynamics (MD) simulations in explicit water to elucidate the molecular interactions of both neutral and ionized species of RvD1 and RvD2 with the lipid bilayer using a model membrane system, containing 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and cholesterol. We found that the differences in the position and chirality of hydroxyl groups in RvD1 and RvD2 affected their location, orientation, and conformations within the bilayer. Surprisingly, the deprotonation of their carboxyl group caused their orientation and conformation to change from a fully extended one that is oriented in parallel to the membrane plane to a J-shaped bent conformation that is oriented perpendicular to the bilayer plane. Our studies offer valuable insight into the molecular interactions of RvD1/D2 with the lipid bilayer in atomistic details and provide a mechanistic explanation for the observed differences in the encapsulation profiles of RvD1 and RvD2, which may facilitate the rational design of nanovesicle-based therapeutics for treating inflammatory diseases.

Entities:  

Keywords:  cell membrane-derived nanovesicles; drug delivery; membrane partitioning; molecular dynamics simulation; nanotechnology; resolvins

Mesh:

Substances:

Year:  2020        PMID: 32374613      PMCID: PMC7313724          DOI: 10.1021/acs.molpharmaceut.0c00299

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  64 in total

1.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors.

Authors:  Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang; Stephanie Yacoubian; Chih-Hao Lee; Rong Yang; Nicos A Petasis; Charles N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 2.  Free radical lipid peroxidation: mechanisms and analysis.

Authors:  Huiyong Yin; Libin Xu; Ned A Porter
Journal:  Chem Rev       Date:  2011-08-23       Impact factor: 60.622

3.  An atomic and molecular view of the depth dependence of the free energies of solute transfer from water into lipid bilayers.

Authors:  Ravindra W Tejwani; Malcolm E Davis; Bradley D Anderson; Terry R Stouch
Journal:  Mol Pharm       Date:  2011-11-08       Impact factor: 4.939

Review 4.  Doxil®--the first FDA-approved nano-drug: lessons learned.

Authors:  Yechezkel Barenholz
Journal:  J Control Release       Date:  2012-03-29       Impact factor: 9.776

5.  Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat.

Authors:  Joan Clària; Jesmond Dalli; Stephanie Yacoubian; Fei Gao; Charles N Serhan
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

6.  Cell membrane-formed nanovesicles for disease-targeted delivery.

Authors:  Jin Gao; Dafeng Chu; Zhenjia Wang
Journal:  J Control Release       Date:  2016-01-14       Impact factor: 9.776

Review 7.  Targeting Inflammatory Vasculature by Extracellular Vesicles.

Authors:  Sihan Wang; Xinyue Dong; Jin Gao; Zhenjia Wang
Journal:  AAPS J       Date:  2018-02-26       Impact factor: 4.009

8.  Topical delivery of aqueous micellar resolvin E1 analog (RX-10045).

Authors:  Kishore Cholkar; Brian C Gilger; Ashim K Mitra
Journal:  Int J Pharm       Date:  2015-12-17       Impact factor: 5.875

Review 9.  Specialized pro-resolving mediators: endogenous regulators of infection and inflammation.

Authors:  Maria C Basil; Bruce D Levy
Journal:  Nat Rev Immunol       Date:  2015-12-21       Impact factor: 53.106

10.  Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis.

Authors:  Matthew Spite; Lucy V Norling; Lisa Summers; Rong Yang; Dianne Cooper; Nicos A Petasis; Roderick J Flower; Mauro Perretti; Charles N Serhan
Journal:  Nature       Date:  2009-10-29       Impact factor: 49.962

View more
  6 in total

Review 1.  Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.

Authors:  Hui Xu; Shuang Li; You-Shuo Liu
Journal:  Signal Transduct Target Ther       Date:  2022-07-11

2.  Membrane Lipids Are an Integral Part of Transmembrane Allosteric Sites in GPCRs: A Case Study of Cannabinoid CB1 Receptor Bound to a Negative Allosteric Modulator, ORG27569, and Analogs.

Authors:  Peter Obi; Senthil Natesan
Journal:  J Med Chem       Date:  2022-09-06       Impact factor: 8.039

3.  Resolvin D1-loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis.

Authors:  Ameya A Dravid; Kaamini M Dhanabalan; Smriti Agarwal; Rachit Agarwal
Journal:  Bioeng Transl Med       Date:  2022-03-07

Review 4.  Nanomedicine for Ischemic Stroke.

Authors:  Xinyue Dong; Jin Gao; Yujie Su; Zhenjia Wang
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

5.  Human neutrophil membrane-derived nanovesicles as a drug delivery platform for improved therapy of infectious diseases.

Authors:  Jin Gao; Xinyue Dong; Yujie Su; Zhenjia Wang
Journal:  Acta Biomater       Date:  2021-01-18       Impact factor: 8.947

6.  Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting β2-Adrenergic Receptor Agonists.

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2021-08-01       Impact factor: 4.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.